Allogene Therapeutics, Inc. (ALLO)
1.94
-0.06
(-3.00%)
USD |
NASDAQ |
May 18, 16:00
1.92
-0.02
(-1.03%)
After-Hours: 04:40
Allogene Therapeutics Research and Development Expense (Quarterly) : 29.13M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 13.75M |
| Agenus, Inc. | 11.82M |
| Vaxart, Inc. | 29.41M |
| Capricor Therapeutics, Inc. | 27.10M |
| Curis, Inc. | 6.449M |